Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 18/20 | 0.57 |
| ▸ | VEGFA | P15692 | 6/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18048381 | 1.00 | EPAS1 (0.57) | EPAS1VEGFA | |
| SCHEMBL18067992 | 1.00 | EPAS1 (0.57) | EPAS1VEGFA | |
| SCHEMBL18067991 | 1.00 | EPAS1 (0.57) | EPAS1VEGFA | |
| SCHEMBL19872188 | 0.92 | EPAS1 (0.56) | EPAS1VEGFA | |
| SCHEMBL18688700 | 0.91 | EPAS1 (0.53) | EPAS1VEGFA | |
| SCHEMBL19870952 | 0.90 | EPAS1 (0.59) | EPAS1VEGFA | |
| SCHEMBL19870950 | 0.88 | EPAS1 (0.55) | EPAS1VEGFA | |
| SCHEMBL20253166 | 0.88 | EPAS1 (0.45) | EPAS1VEGFA | |
| SCHEMBL19870911 | 0.88 | EPAS1 (0.57) | EPAS1VEGFA | |
| SCHEMBL19870906 | 0.88 | EPAS1 (0.57) | EPAS1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180042884-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | PELOTON THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180042884-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | MGMT, NEFM, TUBB3 | EPAS1 2505/4885VEGFA 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.